These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 130137)

  • 1. Cyclophosphamide protection in NZB/NZW disease. Mechanisms and therapeutic regimens.
    Morris AD; Esterly J; Chase G; Sharp GC
    Arthritis Rheum; 1976; 19(1):49-55. PubMed ID: 130137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic studies in NZB/W mice. IV. Effect of combination drug therapy on immune complex deposition.
    Gelfand MC; Schur PH; Asofsky R; Steinberg AD
    Arthritis Rheum; 1976; 19(1):43-8. PubMed ID: 130136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic studies of autoimmunity in New Zealand mice. IV. Contribution of NZB and NZW genes to the spontaneous occurrence of retroviral gp70 immune complexes in (NZB X NZW)F1 hybrid and the correlation to renal disease.
    Maruyama N; Furukawa F; Nakai Y; Sasaki Y; Ohta K; Ozaki S; Hirose S; Shirai T
    J Immunol; 1983 Feb; 130(2):740-6. PubMed ID: 6217253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanism of action of cyclophosphamide on the nephritis of (NZB x NZW)F1 hybrid mice.
    Hurd ER; Ziff M
    Clin Exp Immunol; 1977 Jul; 29(1):132-9. PubMed ID: 302170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/NZW mice.
    Hahn BH; Knotts L; Ng M; Hamilton TR
    Arthritis Rheum; 1975; 18(2):145-52. PubMed ID: 1131283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High incidence of neoplasms in female NZB/NZW mice treated with pulse doses of cyclophosphamide.
    Walker SE; Anver MR
    Vet Immunol Immunopathol; 1983 Nov; 5(1):97-104. PubMed ID: 6606891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostaglandin E1 treatment of NZB/NZW F1 hybrid mice. II. Prevention of glomerulonephritis.
    Zurier RB; Damjanov I; Sayadoff DM; Rothfield NF
    Arthritis Rheum; 1977; 20(8):1449-56. PubMed ID: 144506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acceleration of glomerulonephritis in NZB x NZW mice by early immunization with DNA and injection of bacterial lipopolysaccharide. Experimental approach to the treatment of lupus nephritis by use of the accelerated model of NZB x NZW mouse disease.
    Fournie GJ; Minh MG; Mignon-Conte MA; Hass S; Lambert PH; Conte JJ
    J Clin Lab Immunol; 1980 Sep; 4(2):103-6. PubMed ID: 7441709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of lymphocyte function in NZB/NZW mice. IV. Response to levamisole.
    Hahn BH; Knotts LL
    Arthritis Rheum; 1979 Mar; 22(3):236-42. PubMed ID: 33681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Ig mu-heavy chain transgene inhibits systemic lupus erythematosus immunopathology in autoimmune (NZB x NZW)F1 mice.
    Wellmann U; Letz M; Schneider A; Amann K; Winkler TH
    Int Immunol; 2001 Dec; 13(12):1461-9. PubMed ID: 11717187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization.
    Rudofsky UH; Evans BD; Balaban SL; Mottironi VD; Gabrielsen AE
    Lab Invest; 1993 Apr; 68(4):419-26. PubMed ID: 8479150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribavirin treatment in murine autoimmune disease. I. Therapeutic efficacy and effect on the immune response.
    Klassen LW; Williams GW; Reinertsen JL; Gerber NL; Steinberg AD
    Arthritis Rheum; 1979 Feb; 22(2):145-54. PubMed ID: 33680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An in vivo model for the experimental selection of drugs able to prevent immune complex glomerulonephritis.
    In S; Le Lann AD; Oksman F; Fournié EL; Labarre JF; Benoist H; Fournié GJ
    Int J Immunopharmacol; 1992 Jul; 14(5):871-6. PubMed ID: 1387391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulated autoantibody response and increased longevity in NZB/NZW mice treated with cyclophosphamide and tilorone.
    Walker SE; Anver MR
    Clin Exp Immunol; 1978 Sep; 33(3):453-62. PubMed ID: 737897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Origins of pathogenic anti-DNA idiotypes in the NZB X SWR model of lupus nephritis.
    Datta SK; Gavalchin J
    Ann N Y Acad Sci; 1986; 475():47-58. PubMed ID: 2947530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model.
    Ando DG; Sercarz EE; Hahn BH
    J Immunol; 1987 May; 138(10):3185-90. PubMed ID: 2952711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of thymic factors. II. Failure of thymosin to alter the natural history of NZB and NZB/NZW mice.
    Gershwin ME; Steinberg AD; Ahmed A; Derkay C
    Arthritis Rheum; 1976; 19(5):862-6. PubMed ID: 1085626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of altered lymphocyte function on immunologic disorders in NZB/NZW mice.
    Mehta J; Knotts LL; Hahn BH
    Arthritis Rheum; 1977; 20(1):65-72. PubMed ID: 13801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The differential effects of cyclophosphamide and 6-mercaptopurine on the renal disease and skin immunoglobulin deposits of the NZB-NZW F1 hybrid mice.
    Hurd ER; Gilliam JN; Ziff M
    Agents Actions; 1976 Feb; 6(1-3):364-8. PubMed ID: 782209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine lupus nephritis: effects of cyclophosphamide on circulating and tissue bound immunoreactants.
    Cavallo T; Graves K; Granholm NA
    Clin Exp Immunol; 1984 Jan; 55(1):67-73. PubMed ID: 6607142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.